Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial - Ostadal, P; Steg, P G; Poulouin, Y (Lancet Diabetes Endocrinol, 2022)